Capitol Hill FDA Lists Potentially Avoidable Harms in 20 LDT Case Studies, Including Tests from Duke, Caris and Genomic Health November 20, 2015Vol.41 No.43By Conor Hale
CBER’s All-Day Voyage into Slippery Science Ends in 18-6 Vote against Bladder Drug November 20, 2015Vol.41 No.43By Paul Goldberg
Free J&J Says There Were No Reportable Morcellation Events; Whistleblower Disagrees—and Produces Letters November 19, 2015Vol.41 No.43By Matthew Bin Han Ong
Free FDA: Federal Law Requires Reporting of Morcellation Adverse Events, But None Were Brought to Agency’s Attention For 8 Years November 19, 2015Vol.41 No.43
Free Congressional Panel Chair Questions Whether J&J, Brigham Reported Morcellation Adverse Events to FDA November 19, 2015Vol.41 No.43By Matthew Bin Han Ong
Capitol HillFree Advocacy Organizations Urge Congress to Consider FDA’s Expertise in Regulating Lab-Developed Tests November 13, 2015Vol.41 No.42
